EUVIMEDEUVIMED entdecken
Randomisierte kontrollierte StudieOpen Access

Differential Treatment Effects on β-Cell Function Using Model-Based Parameters in Type 2 Diabetes: Results From the Glycemia Reduction Approaches in Diabetes: A Comparative Effectiveness Study (GRADE)

Kristina M Utzschneider iD, Mark Tripputi, Nicole M Butera iD, Andrea Mari iD, Samuel P Rosin, Mary Ann Banerji iD, Richard M Bergenstal iD, Necole Brown, Anders L Carlson, Ralph A DeFronzo iD, Michaela R Gramzinski iD, Tasma Harindhanavudhi und 6 weitere

Diabetes Care · 2025

DOI: 10.2337/dc24-2419 ↗

Kurz gefasst

Randomisierte kontrollierte Studie in der Zeitschrift Diabetes Care, 2025. Verfasst von Kristina M Utzschneider und 17 weiteren Autor:innen. Beteiligte Einrichtung: Division of Metabolism, Endocrinology and Nutrition, Department of Medicine, VA Puget Sound Health Care System and University of Washington, Seattle,…. Hauptthemen laut MEDLINE: Diabetes Mellitus, Type 2, Insulin-Secreting Cells, Hypoglycemic Agents, Blood Glucose. Die Arbeit wurde bisher 4-mal zitiert (Crossref) und nennt 28 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: NCATS NIH HHS, NIDDK NIH HHS, NHLBI NIH HHS.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

OBJECTIVE To evaluate how model-based parameters of β-cell function change with glucose-lowering treatment and associate with glycemic deterioration in adults with type 2 diabetes (T2D). RESEARCH DESIGN AND METHODS In the Glycemia Reduction Approaches in Diabetes: A Comparative Effectiveness Study (GRADE), β-cell function parameters derived from mathematical modeling of oral glucose tolerance tests were assessed at baseline (N = 4,712) and 1, 3, and 5 years following randomization to insulin glargine, glimepiride, liraglutide, or sitagliptin, added to baseline metformin. Parameters included insulin secretion rate (ISR), glucose sensitivity (insulin response to glucose), rate sensitivity (early insulin response), and potentiation. Linear mixed-effects models were used to compare changes across treatments. With Cox proportional hazards and Classification And Regression Tree (CART) analyses we evaluated associations between model parameters and glycemic failure (A1C >7.5%; 58.5 mmol/mol). RESULTS β-Cell function parameters increased variably at year 1 across treatments but subsequently declined for all treatments. Statistically significant changes were noted. Liraglutide led to the greatest increases in ISR, glucose sensitivity and potentiation, remaining above baseline at study end. Sitagliptin improved glucose sensitivity, with modest effects on other parameters. Glimepiride temporarily increased ISR and rate sensitivity but minimally increased glucose sensitivity or potentiation. Rate sensitivity increased most with glargine. Higher β-cell function parameters were protective against glycemic deterioration, but treatment did not alter the relationship between these parameters and glycemic outcomes. CONCLUSIONS Common glucose-lowering medications impact different physiologic components of β-cell function in T2D. Regardless of treatment modality, lower β-cell function associated with early glycemic failure, and β-cell function progressively declined after initial improvement.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Diabetes Mellitus, Type 2Insulin-Secreting CellsHypoglycemic AgentsBlood GlucoseHumansMaleMiddle AgedSulfonylurea CompoundsFemaleMetforminSitagliptin PhosphateLiraglutideInsulin GlargineAgedGlucose Tolerance Test

Substanzen

Hypoglycemic AgentsSulfonylurea CompoundsMetforminBlood GlucoseSitagliptin PhosphateLiraglutideglimepirideInsulin Glargine

Autor:innen und Institutionen

  • Division of Metabolism, Endocrinology and Nutrition, Department of Medicine, VA Puget Sound Health Care System and University of Washington, Seattle, WA.
  • The Biostatistics Center, Department of Biostatistics and Bioinformatics, Milken Institute School of Public Health, The George Washington University, Rockville, MD.
  • Institute of Neuroscience, National Research Council, Padova, Italy.
  • Division of Endocrinology and Department of Medicine, State University of New York Downstate Medical Center and Kings County Hospital, Brooklyn, NY.
  • International Diabetes Center, HealthPartners Institute, Minneapolis, MN.
  • University of Texas Health Science Center, San Antonio, TX.

ORCID-Profile: Kristina M Utzschneider, Nicole M Butera, Andrea Mari, Mary Ann Banerji, Richard M Bergenstal, Ralph A DeFronzo, Michaela R Gramzinski, William I Sivitz, Ashok Balasubramanyam, Neda Rasouli

Förderung

  • NCATS NIH HHS
  • NIDDK NIH HHS
  • NHLBI NIH HHS
  • Centers for Disease Control and Prevention Foundation
  • American Diabetes Association
  • NIGMS NIH HHS
  • National Institute of Diabetes and Digestive and Kidney Diseases
  • National Heart, Lung, and Blood Institute

Zitieren

APA

Utzschneider, K. M., Tripputi, M., Butera, N. M., Mari, A., Rosin, S. P., Banerji, M. A., Bergenstal, R. M., Brown, N., Carlson, A. L., DeFronzo, R. A., Gramzinski, M. R., Harindhanavudhi, T., Kozedub, A., Sivitz, W. I., Steffes, M. W., Balasubramanyam, A., Rasouli, N., & GRADE Research Group (2025). Differential Treatment Effects on β-Cell Function Using Model-Based Parameters in Type 2 Diabetes: Results From the Glycemia Reduction Approaches in Diabetes: A Comparative Effectiveness Study (GRADE). Diabetes Care. https://doi.org/10.2337/dc24-2419

Vancouver

Utzschneider KM, Tripputi M, Butera NM, Mari A, Rosin SP, Banerji MA, et al. Differential Treatment Effects on β-Cell Function Using Model-Based Parameters in Type 2 Diabetes: Results From the Glycemia Reduction Approaches in Diabetes: A Comparative Effectiveness Study (GRADE). Diabetes Care. 2025. doi:10.2337/dc24-2419

BibTeX
@article{Utzschneider2025,
  author = {Utzschneider, Kristina M and Tripputi, Mark and Butera, Nicole M and Mari, Andrea and Rosin, Samuel P and Banerji, Mary Ann and Bergenstal, Richard M and Brown, Necole and Carlson, Anders L and DeFronzo, Ralph A and Gramzinski, Michaela R and Harindhanavudhi, Tasma and Kozedub, Alexandra and Sivitz, William I and Steffes, Michael W and Balasubramanyam, Ashok and Rasouli, Neda and GRADE Research Group, GRADE Research Group},
  title = {Differential Treatment Effects on β-Cell Function Using Model-Based Parameters in Type 2 Diabetes: Results From the Glycemia Reduction Approaches in Diabetes: A Comparative Effectiveness Study (GRADE)},
  journal = {Diabetes Care},
  year = {2025},
  doi = {10.2337/dc24-2419}
}
Kostenlos starten →